Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs

被引:2
|
作者
Balogh, Erin P. [1 ]
Bindman, Andrew B. [2 ]
Eckhardt, S. Gail [3 ]
Halabi, Susan [4 ]
Harvey, R. Donald [5 ]
Jaiyesimi, Ishmael [6 ]
Miksad, Rebecca [7 ]
Moses, Harold L. [8 ]
Nass, Sharyl J. [1 ]
Schilsky, Richard L. [9 ]
Sun, Steven [10 ]
Torrente, Josephine M. [11 ]
Warren, Katherine E. [12 ]
机构
[1] Natl Acad Sci Engn & Med, Hlth & Med Div, 500 Fifth St NW, Washington, DC 20001 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA
[4] Duke Univ, Durham, NC USA
[5] Emory Univ, Atlanta, GA 30322 USA
[6] Beaumont Hosp, Royal Oak, MI USA
[7] Flatiron Hlth, New York, NY USA
[8] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[9] Amer Soc Clin Oncol, Alexandria, VA USA
[10] Janssen Res & Dev, Raritan, NJ USA
[11] Hyman Phelps & McNamara PC, Washington, DC USA
[12] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA
来源
ONCOLOGIST | 2020年 / 25卷 / 03期
关键词
Cancer; Drug prescriptions; Drug legislation; Drug approval; Pharmaceutical research;
D O I
10.1634/theoncologist.2019-0698
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A number of important drugs used to treat cancer-many of which serve as the backbone of modern chemotherapy regimens-have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice.
引用
收藏
页码:E405 / E411
页数:7
相关论文
共 50 条
  • [31] Global oncology in the Covid era: Challenges and opportunities
    Mckay, Gary
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 93 - 93
  • [33] Optimal Prescribing and Medication Use in Canada: Challenges and Opportunities
    Sketris, Ingrid
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2008, 61 : 39 - 39
  • [34] Radiotheranostics in oncology: current challenges and emerging opportunities
    Lisa Bodei
    Ken Herrmann
    Heiko Schöder
    Andrew M. Scott
    Jason S. Lewis
    Nature Reviews Clinical Oncology, 2022, 19 : 534 - 550
  • [35] Opportunities and Challenges of Synthetic Data Generation in Oncology
    Jacobs, Flavia
    D'Amico, Saverio
    Benvenuti, Chiara
    Gaudio, Mariangela
    Saltalamacchia, Giuseppe
    Miggiano, Chiara
    De Sanctis, Rita
    Della Porta, Matteo Giovanni
    Santoro, Armando
    Zambelli, Alberto
    JCO CLINICAL CANCER INFORMATICS, 2023, 7 : e2300045
  • [36] Radiotheranostics in oncology: current challenges and emerging opportunities
    Bodei, Lisa
    Herrmann, Ken
    Schoeder, Heiko
    Scott, Andrew M.
    Lewis, Jason S.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (08) : 534 - 550
  • [37] Opportunities and Challenges of Defining "Value" in Oncology Care
    Mott, Nicole M.
    Dossett, Lesly A.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (11) : 6518 - 6519
  • [38] Opportunities and Challenges of Synthetic Data Generation in Oncology
    Jacobs, Flavia
    D'Amico, Saverio
    Benvenuti, Chiara
    Gaudio, Mariangela
    Saltalamacchia, Giuseppe
    Miggiano, Chiara
    De Sanctis, Rita
    Della Porta, Matteo Giovanni
    Santoro, Armando
    Zambelli, Alberto
    JCO CLINICAL CANCER INFORMATICS, 2023, 7
  • [39] Incorporating AI into oncology practice: Opportunities and challenges
    Burris, Howard A.
    ANNALS OF ONCOLOGY, 2021, 32 : S232 - S232
  • [40] Overview of precision oncology trials: challenges and opportunities
    Fountzilas, Elena
    Tsimberidou, Apostolia M.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (08) : 797 - 804